CXCR4 and non-small cell lung carcinoma: We prove the ability of a new class of CXCR4 antagonists (44) to counteract the immune suppressive behavior of metastatic NSCLC stem cells, pointing at CXCR4 as novel target to prevent metastatic dissemination and immune escape mechanisms exploited by MICs.